TCL Archive Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up December 26, 2014
TCL Archive Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis December 27, 2013
TCL Archive In Brief: Hellman Will Leave Harvard To Become Physician In Chief At Memorial. James Awards Announced April 22, 1983